This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
AOP: 578
Title
AhR activation leading to cancer progression via immunosuppression
Short name
Graphical Representation
Point of Contact
Contributors
- Léo SPORTES-MILOT
- Etienne Blanc
- Xavier COUMOUL
Coaches
OECD Information Table
OECD Project # | OECD Status | Reviewer's Reports | Journal-format Article | OECD iLibrary Published Version |
---|---|---|---|---|
This AOP was last modified on June 11, 2025 06:03
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Activation, AhR | May 31, 2025 07:56 |
Over-expression of PD-L1 in cancer cells | May 15, 2025 12:40 |
Dysregulation of Treg/Th17 cell ratio | May 19, 2025 08:38 |
Decreased number of LT CD8+ cells | June 11, 2025 05:41 |
Inhibition of LTCD8+ cells | May 22, 2025 12:01 |
Increased, tumor growth | February 29, 2024 06:05 |
Activation, AhR leads to Over-expression of PD-L1 in cancer cells | May 16, 2025 04:14 |
Over-expression of PD-L1 in cancer cells leads to Dysregulation of Treg/Th17 cells ratio | May 16, 2025 04:46 |
Dysregulation of Treg/Th17 cells ratio leads to Inhibition of LTCD8+ cells | May 22, 2025 12:01 |
Dysregulation of Treg/Th17 cells ratio leads to Decreased number of LT CD8+ cells | May 16, 2025 05:12 |
Inhibition of LTCD8+ cells leads to tumor growth | June 10, 2025 09:59 |
Decreased number of LT CD8+ cells leads to tumor growth | June 10, 2025 10:00 |
Abstract
Due to the evolution of our society, numerous chemical compounds are created, produced, and released into the environment. However, the impact on the environment and human health remains to be demonstrated for many of them. The AhR receptor is known to be an essential receptor in the metabolism of these xenobiotics. Moreover, AhR regulates many cellular signaling pathways, notably in immunity. Thus, the over-activation of AhR could lead to harmful effects. This AOP focuses on the mechanisms linking AhR activation (MIE) and immunosuppression that can lead to tumor progression (AO).
A literature analysis using artificial intelligences such as AOP-helpfinder or Perplexity highlighted 55 articles. After analyzing these articles, clear links between AhR activation, PD-L1 (Program Death Ligand) expression, the impact on lymphocytes, and finally cancer progression were identified as KEs and KER.
These analyses bring together scientific results in vitro and in vivo, several types of cancers in humans and animals, as well as reviews and articles.
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
MIE | 18 | Activation, AhR | Activation, AhR |
KE | 2323 | Over-expression of PD-L1 in cancer cells | Over-expression of PD-L1 in cancer cells |
KE | 2324 | Dysregulation of Treg/Th17 cell ratio | Dysregulation of Treg/Th17 cells ratio |
KE | 2325 | Decreased number of LT CD8+ cells | Decreased number of LT CD8+ cells |
KE | 2326 | Inhibition of LTCD8+ cells | Inhibition of LTCD8+ cells |
AO | 1971 | Increased, tumor growth | tumor growth |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Network View
Prototypical Stressors
Life Stage Applicability
Taxonomic Applicability
Sex Applicability
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Evidence Assessment
Known Modulating Factors
Modulating Factor (MF) | Influence or Outcome | KER(s) involved |
---|---|---|